Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024 - Episode 3

5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

,

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML
    EP. 2: Factors That Influence Treatment Decisions in Later-Line CML
    Now Viewing
    EP. 3: 5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial
    EP. 4: Emerging Mutation Analysis from the OPTIC Trial
    EP. 5: Dosing Strategies for Ponatinib in CML and ALL
    EP. 6: The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL
    EP. 7: Selecting a TKI in Subsequent Lines of Therapy in CML
    EP. 8: Highlighting Key CML/ALL Data Presented at ASH 2024
    x